News ArchivesRead News
Rave drug sparks hope for treating Parkinson’s
Wednesday June 20, 2012
bioscholar - Rave culture’s illicit drug ‘ecstasy’ can help develop drugs that curb involuntary movements in Parkinson’s disease, says a study.
A team led by a medicinal chemist at The University of Western Australia (UWA) studied the possibility. Matthew Piggott, associate professor, said Parkinson’s patients have a great deal of difficulty moving without medication.
The drug, levodopa, restores their movement but, over time, side-effects often develop. These include a reduction in therapeutic duration and jerky, involuntary movements known as dyskinesia.
“Dyskinesia is often confused as a symptom of Parkinson’s disease, when in fact it is a side-effect of the treatment,” Piggott was quoted as saying in the Journal of the Federation of American Societies for Experimental Biology.
“For some time now we’ve known that the drug most commonly sold as ‘ecstasy’, methylenedioxymethamphetamine (MDMA), ameliorates the side-effects of levodopa therapy. But MDMA has no therapeutic potential because it makes users ‘high’,” said Piggot, according to a university statement.
“Although controversial, there is also evidence that MDMA may be neurotoxic, or at least responsible for long-term, deleterious changes in brain chemistry,” Piggot said.
The team of UWA scientists, collaborating with Parkinson’s disease experts in Toronto, has now demonstrated that it is possible to de-link the beneficial effects of MDMA from its undesirable attributes. The feat was achieved through the creation of MDMA analogues – new compounds with a similar chemical structure to MDMA.
“The best compound, which we call UWA-101, is even more effective than MDMA at enhancing the quality of levodopa therapy,” said Piggot.
If translated to a medicine, this would mean that Parkinson’s patients could take their medication less frequently and get a better quality result from it,” Piggot added.
Disclaimer: Bioscholar is not intended to provide medical advice, diagnosis or treatment. The articles are based on peer reviewed research, and discoveries/products mentioned in the articles may not be approved by the regulatory bodies.
Recent NewsMay 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis
Apr 12 - Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease
Apr 11 - Seattle boxing gym giving hope to Parkinson's patients
Apr 10 - A new rhythm
Apr 10 - Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapy
Apr 6 - FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Apr 5 - Combatting the isolation of young onset Parkinson's disease
Apr 1 - The Kid is Alright
Mar 30 - Hepatitis Tied to Parkinson's Risk
Mar 28 - Elon Musk's new company said to see brain-computer link